282 related articles for article (PubMed ID: 27203208)
21. 6-Substituted purines as ROCK inhibitors with anti-metastatic activity.
Voller J; Zahajská L; Plíhalová L; Jeřábková J; Burget D; Pataki AC; Kryštof V; Zatloukal M; Brábek J; Rösel D; Mik V; Tkáč M; Pospíšil T; Gucký T; Doležal K; Strnad M
Bioorg Chem; 2019 Sep; 90():103005. PubMed ID: 31271944
[TBL] [Abstract][Full Text] [Related]
22. Targeting ROCK signaling in health, malignant and non-malignant diseases.
Shahbazi R; Baradaran B; Khordadmehr M; Safaei S; Baghbanzadeh A; Jigari F; Ezzati H
Immunol Lett; 2020 Mar; 219():15-26. PubMed ID: 31904392
[TBL] [Abstract][Full Text] [Related]
23. The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway.
Laezza C; Pisanti S; Malfitano AM; Bifulco M
Endocr Relat Cancer; 2008 Dec; 15(4):965-74. PubMed ID: 18676619
[TBL] [Abstract][Full Text] [Related]
24. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
[TBL] [Abstract][Full Text] [Related]
25. Targeting ROCK/LIMK/cofilin signaling pathway in cancer.
Lee MH; Kundu JK; Chae JI; Shim JH
Arch Pharm Res; 2019 Jun; 42(6):481-491. PubMed ID: 31030376
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Rho-Associated Kinase 1/2 Attenuates Tumor Growth in Murine Gastric Cancer.
Hinsenkamp I; Schulz S; Roscher M; Suhr AM; Meyer B; Munteanu B; Fuchser J; Schoenberg SO; Ebert MP; Wängler B; Hopf C; Burgermeister E
Neoplasia; 2016 Aug; 18(8):500-11. PubMed ID: 27566106
[TBL] [Abstract][Full Text] [Related]
27. Anti-inflammatory mechanism of ulinastatin: Inhibiting the hyperpermeability of vascular endothelial cells induced by TNF-α via the RhoA/ROCK signal pathway.
Wei F; Liu S; Luo L; Gu N; Zeng Y; Chen X; Xu S; Zhang D
Int Immunopharmacol; 2017 May; 46():220-227. PubMed ID: 28329735
[TBL] [Abstract][Full Text] [Related]
28. The RhoA-ROCK-PTEN pathway as a molecular switch for anchorage dependent cell behavior.
Yang S; Kim HM
Biomaterials; 2012 Apr; 33(10):2902-15. PubMed ID: 22244698
[TBL] [Abstract][Full Text] [Related]
29. Low-Dose Endothelial Monocyte-Activating Polypeptide-II Increases Blood-Tumor Barrier Permeability by Activating the RhoA/ROCK/PI3K Signaling Pathway.
Li Z; Liu XB; Liu YH; Xue YX; Liu J; Teng H; Xi Z; Yao YL
J Mol Neurosci; 2016 Jun; 59(2):193-202. PubMed ID: 26521255
[TBL] [Abstract][Full Text] [Related]
30. The GNA13-RhoA signaling axis suppresses expression of tumor protective Kallikreins.
Teo CR; Casey PJ; Rasheed SA
Cell Signal; 2016 Oct; 28(10):1479-88. PubMed ID: 27424208
[TBL] [Abstract][Full Text] [Related]
31. High glucose activates Raw264.7 macrophages through RhoA kinase-mediated signaling pathway.
Cheng CI; Chen PH; Lin YC; Kao YH
Cell Signal; 2015 Feb; 27(2):283-92. PubMed ID: 25446262
[TBL] [Abstract][Full Text] [Related]
32. ROCK inhibition promotes microtentacles that enhance reattachment of breast cancer cells.
Bhandary L; Whipple RA; Vitolo MI; Charpentier MS; Boggs AE; Chakrabarti KR; Thompson KN; Martin SS
Oncotarget; 2015 Mar; 6(8):6251-66. PubMed ID: 25749040
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
You KS; Yi YW; Kwak SJ; Seong YS
Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
[TBL] [Abstract][Full Text] [Related]
34. Rho kinase inhibitors: potential treatments for diabetes and diabetic complications.
Zhou H; Li YJ
Curr Pharm Des; 2012; 18(20):2964-73. PubMed ID: 22571664
[TBL] [Abstract][Full Text] [Related]
35. Sodium tanshinone IIA sulfonate promotes endothelial integrity via regulating VE-cadherin dynamics and RhoA/ROCK-mediated cellular contractility and prevents atorvastatin-induced intracerebral hemorrhage in zebrafish.
Zhou ZY; Huang B; Li S; Huang XH; Tang JY; Kwan YW; Hoi PM; Lee SM
Toxicol Appl Pharmacol; 2018 Jul; 350():32-42. PubMed ID: 29730311
[TBL] [Abstract][Full Text] [Related]
36. Potently inhibiting cancer cell migration with novel 3H-pyrazolo[4,3-f]quinoline boronic acid ROCK inhibitors.
Dayal N; Mikek CG; Hernandez D; Naclerio GA; Yin Chu EF; Carter-Cooper BA; Lapidus RG; Sintim HO
Eur J Med Chem; 2019 Oct; 180():449-456. PubMed ID: 31330446
[TBL] [Abstract][Full Text] [Related]
37. Lysophosphatidic acid induces a migratory phenotype through a crosstalk between RhoA-Rock and Src-FAK signalling in colon cancer cells.
Leve F; Marcondes TG; Bastos LG; Rabello SV; Tanaka MN; Morgado-Díaz JA
Eur J Pharmacol; 2011 Dec; 671(1-3):7-17. PubMed ID: 21968138
[TBL] [Abstract][Full Text] [Related]
38. Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression.
Borin TF; Arbab AS; Gelaleti GB; Ferreira LC; Moschetta MG; Jardim-Perassi BV; Iskander AS; Varma NR; Shankar A; Coimbra VB; Fabri VA; de Oliveira JG; Zuccari DA
J Pineal Res; 2016 Jan; 60(1):3-15. PubMed ID: 26292662
[TBL] [Abstract][Full Text] [Related]
39. Involvement of RhoA/ROCK in insulin secretion of pancreatic β-cells in 3D culture.
Liu X; Yan F; Yao H; Chang M; Qin J; Li Y; Wang Y; Pei X
Cell Tissue Res; 2014 Nov; 358(2):359-69. PubMed ID: 25129107
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells.
Gilkes DM; Xiang L; Lee SJ; Chaturvedi P; Hubbi ME; Wirtz D; Semenza GL
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):E384-93. PubMed ID: 24324133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
